Every material Form 8-K Neuphoria Therapeutics Inc. has filed with the SEC since May 26, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neuphoria Therapeutics entered into Amendment No. 1 to its shareholder Rights Agreement on October 23, 2026, extending the plan's Final Expiration Date to the close of business on October 27, 2027, unless earlier extended, modified or terminated. The filing reports this as a material modification to the rights of security holders, so shareholders should note that the plan now remains in effect for an additional period.
Amendment No. 1 to the Rights Agreement dated October 23, 2026, between Neuphoria and Computershare Trust Company, N.A., as Rights Agent
Final Expiration Date extended to the close of business on October 27, 2027, unless earlier extended, modified or terminated
Original Rights Agreement dated October 27, 2025; the filing reports it as a material modification to security holder rights (Item 3.03)
Neuphoria Therapeutics signed a merger agreement on July 23, 2026, under which Merger Sub will merge into Neuphoria and Neuphoria will become an indirect wholly owned subsidiary of Scancell Holdings plc. Neuphoria stockholders would receive Scancell ADSs at an exchange ratio of 37.77199 per share plus one contingent value right, and the deal is subject to shareholder approvals, financing and Nasdaq listing conditions. Neuphoria stockholders are expected to own about 11.1% of the combined company, and the filing describes the company as having no ongoing revenue and one employee.
Exchange ratio of 37.77199 Scancell ADSs per Neuphoria common share, plus one CVR per share
Pre-merger Neuphoria stockholders expected to own approximately 11.1% of the combined company
Closing conditions include Neuphoria stockholder approval and at least $75.0 million in gross PIPE proceeds; the merger must close by February 28, 2027 unless extended
Companion release says Neuphoria had $19.4 million in cash as of March 31, 2026 and a net loss of $0.5 million for the quarter ended March 31, 2026
On May 21, 2026, Neuphoria received a revenue distribution of AUD $1.416 million from its participation in the former CTx CRC, linked to its KAT6 license to Pfizer after dosing began in the first Phase III trial in ER+/HER2- metastatic breast cancer. The company believes it may receive about 4.65% of future milestone payments from CTx CRC, which it estimates total USD $460 million across all 17 parties, but it cannot determine whether those milestones will be achieved or what any payments would be.
Distribution of AUD $1,416,026 related to the KAT6 program license to Pfizer, received May 21, 2026
Company believes it is eligible for about 4.65% of future milestone payments, estimated at USD $460 million total for all 17 parties
Total CRC trust distributions to the company since 2016 are AUD $3,522,413.68
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neuphoria Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →